Novo Nordisk | NVO - Des Atouts





Des Atouts Changement Date
ANI Pharmaceuticals USD 1.49B 72.14M 2026-06
Aurora Cannabis CAD 601.09M 174.2M 2026-03
Bausch Health Companies USD 24.79B 296M 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Canopy Growth CAD 1.12B 12.54M 2026-03
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Drreddys Laboratories INR 579.35B 573.08B 2026-03
Eli Lilly USD 142.28B 25.71B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Merck USD 129.8B 1.12B 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Novartis USD 122.03B 3.5B 2026-06
Novo Nordisk DKK 594.94B 35.72B 2026-06
Novo Nordisk DKK 90.92B 468.3B 2026-06
Pacira USD 1.24B 35.44M 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Phibro Animal Health USD 1.5B 56.12M 2026-06
Prestige Brands USD 4.57B 1.07B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
Supernus Pharmaceuticals USD 1.43B 72.62M 2026-06
Zoetis USD 15.08B 77M 2026-06